The End­points Slack in­ter­view: How Beam CEO John Evans thinks about the sci­ence and busi­ness of ge­net­ic edit­ing

Even with last year’s land­mark ap­provals for ge­net­ic med­i­cines in sick­le cell dis­ease, John Evans is con­vinced his start­up can push the field fur­ther.

Beam Ther­a­peu­tics start­ed 2024 by an­nounc­ing it had dosed the first sick­le cell pa­tient with its base-edit­ing pro­gram, ex­pect­ing ini­tial hu­man re­sults in the sec­ond half of 2024. End­points News in­vit­ed Evans, a for­mer Agios Phar­ma­ceu­ti­cals ex­ec­u­tive who has run Beam since 2017, to our se­cret Slack chan­nel to talk about Beam’s sick­le cell plans amid in­creas­ing com­pe­ti­tion, as well as how CRISPR could evolve over the next two decades.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER